SuRE™ Technology Screening services
Identification of regulatory DNA elements as well as the genetic variation in these elements that define traits and diseases in humans, plants and animals.
SuRE™ screening to identify promoters for better control over the expression of your transgene.
Assay the functional impact of non-coding mutations for entire genomes or specific mutation panels.
SuRE™ reporter libraries for monitoring of multiple pathways during compound screens.
Our novel technology in 2 steps
The SuRE method is in essence a strategy to analyze millions of DNA elements for their activity as promoters or enhancers in a single experiment. By analyzing ~300 million DNA elements of ~300bp length, an entire human genome can be analyzed exhaustively at an approximate 30 fold coverage.
The only required input is DNA and once a SuRE library is established it can analyzed and compared to other DNA sources in the controlled environment of any transfectable cell type. Thus, without the requirement of invasive biopsies, any genome of interest can be analyzed in relevant cell types and under relevant (e.g. stimulatory) conditions.
We first construct a plasmid library containing millions of DNA elements. A human genome is randomly sheared, size-selected and cloned into a plasmid library that contains no promoter of its own. These plasmids contain a unique 20bp sequence referred to as a barcode which allows us to uniquely identify and follow each cloned DNA element. This library is characterized (i.e. barcodes are associated to their respective DNA element) by paired-end sequencing.
Fragmented human genome
0.2 - 2 kb
Plasmid library containing > 300 million DNA elements
Library Expression Profiling
In step 2, the plasmid library is transfected into a cell type of interest. DNA elements containing promoters or enhancers will transcribe the barcode which can now be detected in the RNA by high-throughput sequencing. By comparing these barcode frequencies with the frequencies in the plasmid library, a quantitative map of promoter and enhancer activity can be constructed for the human genome.
Transfection plasmid library into ~1*10 cells
Quantify expressed barcodes
Quantify all barcodes
Promoter and enhancer activity for entire genome
Introducing our experts
We have a team of ten highly skilled and enthusiastic scientists and technicians dedicated to our clients projects. In addition, they work on new developments around our SuRE™ platform to ensure its continuous improvement for pharmaceutical and agricultural applications. The team is led by founder Joris van Arensbergen and biotech entrepreneur Victor Schut.
Annogen signs collaboration agreement with Tier 1 agricultural firm to research non-coding DNA influencing gene expression using SuRE™ screening technology
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agricultural firm to identify non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits. This will open new possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
Annogen and KeyGene to collaborate in research on non-coding DNA influencing gene expression
Annogen and KeyGene the Wageningen based research company developing innovative technologies for crop improvement, are to collaborate in identifying non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits. This will open new possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
Annogen incorporated to commercialize SuRE technology for Functional Genome Annotation.
Sister company Gen-X BV has just signed an exclusive deal for use of SuRE for gene therapy with uniQure and consequently, Annogen was incorporated with exclusive rights to commercialize the technology outside the gene therapy field.
February 1, 2020 - Annogen appoints Victor Schut as Chief Business Officer
After supporting sister company Gen-X as CBO in 2019 and following the recent execution of its exclusive deal with Dutch gene therapy company uniQure he will now focus on setting up the spin-off business around the SuRE technology outside the gene therapy field.